This page shows the latest AbCellera news and features for those working in and with pharma, biotech and healthcare.
An antibody targeting variants of COVID-19, developed as part of a collaboration between Eli Lilly and Canadian biotech company AbCellera, has entered clinical trials. ... AbCellera added that LY-CoV1404 is ‘substantially more potent’ in viral
The mAb is being developed in collaboration with AbCellera, following a co-development agreement signed in March for COVID-19 treatments. ... LY-CoV555 is the result of this early screening, and is now the lead candidate from Lilly’s collaboration with
The collaboration will leverage AbCellera’s pandemic response platform and Lilly’s global capabilities for the rapid development and subsequent manufacturing and distribution of therapeutic antibodies. ... AbCellera's platform has delivered, with
More from news
Approximately 3 fully matching, plus 0 partially matching documents found.
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...